Contraindications to receiving the Prevnar 20 (PCV20) vaccine documented in Wyeth Pharmaceuticals package insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of PCV20 or any vaccine containing diphtheria toxoid.
There is no safety or immunogenicity information on the use of PCV20 in persons who are immunocompromised. Persons with altered immune systems may have a reduced response to vaccination with PCV20.
Data on the administration of PCV20 to women who are pregnant is insufficient for Wyeth pharmaceuticals to provide any information on the risks of vaccination during pregnancy. There is no available data on the effects of PCV20 on the breast-fed infant and it is recommended that breastfeeding women carefully consider the possible risk of vaccination on the infant when considering this vaccine.
PCV20 is approved for individuals six weeks of age and older. Individuals under the age of six weeks should not receive PCV20.
